Figure 3
From: A novel lipidic peptide with potential to promote balanced effector-regulatory T cell responses
IK14004 enhances expression of activating co-receptors in CD8+ T cells and induces STAT5 activation. Experiments with PBMCs or isolated CD3+ T cells were performed using triplicate wells (technical replicates) for each experiment and flow cytometry experiments were repeated four times (n = experimental replicates) as indicated below each panel. All error bars represent standard error of the mean (SEM). Cells were cultured for 48 h in a granzyme B assay (CD107a) and in all other experiments for 72 h. The granzyme B assay is described in the “Methods”. The compound shown is IK14004 as indicated under each panel. Flow cytometry data are shown as percentages and mean fluorescence intensity (MFI). Dot plots and gating strategies are shown in Supplementary Figs. S18 to S27. (a) Percentage of CD28 + CD8 + T cells within PBMC cultures. (b) Percentage of Ki67 + CD28 + CD8 + T cells within PBMC cultures. (c) Percentage of CD28 + CD4 + T cells within PBMC cultures. (d) Percentage of Ki67 + CD28 + CD4 + T cells within PBMC cultures. (e) Expression of NKG2D in CD8 + T cells within PBMC cultures. (f) Percentage of CD107a + CD8 + T cells within a PBMC : K562 co-culture assay. (g) Expression of pSTAT5 in CD8+ T cells within T cell cultures. (h) Percentage of pSTAT5-expressing CD8+ T cells within T cell cultures. (i) Expression of pSTAT5 in CD4+ T cells within T cell cultures. (j) Percentage of pSTAT5-expressing CD4+ T cells within T cell cultures. Data were analysed using repeated measures (RM) two-way ANOVA with Dunnett’s post-test comparing peptide with vehicle control. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
